The FDA has granted Lilly's abemaciclib breakthrough therapy designation for the treatment of advanced breast cancer.
The designation comes on the back of data from Lilly's phase I JPBA trial which studied the efficacy and safety of abemaciclib in women with advanced or metastic breast cancer who had received a median of seven prior treatments.
Richard Gaynor, senior VP of product development and medical affairs for Lilly, said:
